A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

NCT07477704 · tracked via the Priya Life Science USA tracker

Sponsor

Regeneron Pharmaceuticals

Phase

Phase 2

Started

2026-06-17

Last updated

2026-07-22

Condition(s) studied

Hypercholesterolemia

Investigational drug(s) / intervention(s)

Alirocumab

Alirocumab: Administered per the protocol

Study summary

This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels).

The aim of the study is to see how safe and effective alirocumab is when given weekly to adult participants who have hypercholesterolemia.

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drug once a week
* How much study drug is in the blood at different times

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Key Inclusion Criteria: 1\. Participant has elevated LDL-C level, as defined in the protocol Key Exclusion Criteria: 1. Participant plans to initiate or change dose of lipid-lowering therapy 2. Use of any PCSK9 inhibitors NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply

Primary outcome measure(s)

Percent change in LDL-C — From Baseline through Week 12

Trial sites (34)

Facility	City	Region	Status
Pinnacle Research Group	Anniston	Alabama	Recruiting
Cullman Clinical Trials	Cullman	Alabama	Recruiting
Anaheim Clinical Trials	Anaheim	California	Recruiting
Cenexel CNS	Los Alamitos	California	Recruiting
Diablo Clinical Research - Flourish Research	Walnut Creek	California	Recruiting
Tampa Bay Medical Research	Clearwater	Florida	Recruiting
Southwest General Healthcare Center	Fort Myers	Florida	Recruiting
Precision Clinical Research	Sunrise	Florida	Recruiting
K2 Medical Research The Villages	The Villages	Florida	Recruiting
Center for Advanced Research and Education	Gainesville	Georgia	Recruiting
Balanced Life Health Care Solutions	Lawrenceville	Georgia	Recruiting
East-West Medical Research Institute	Honolulu	Hawaii	Recruiting
L-MARC Research Center	Louisville	Kentucky	Recruiting
Tandem Clinical Research	Marrero	Louisiana	Recruiting
Mercury Street Medical Group, PLLC	Butte	Montana	Recruiting
Velocity Clinical Research - Omaha	Omaha	Nebraska	Recruiting
Palm Research Center, Mountainview Medical Center	Las Vegas	Nevada	Recruiting
Velocity Clinical Research - Durham	Durham	North Carolina	Recruiting
Accellacare of Wilmington	Wilmington	North Carolina	Recruiting
Ohio Clinical Trials	Columbus	Ohio	Recruiting
AMR Norman	Norman	Oklahoma	Recruiting
Lynn Health Science Institute	Oklahoma City	Oklahoma	Recruiting
Velocity Clinical Research, Medford	Medford	Oregon	Recruiting
Altoona Center for Clinical Research	Duncansville	Pennsylvania	Recruiting
Tribe Clinical Research	Greenville	South Carolina	Recruiting
Coastal Carolina Research Center_North Charleston	North Charleston	South Carolina	Recruiting
Velocity Clinical Research Dallas	Dallas	Texas	Recruiting
Valley Institute of Research, Rockwood Medical Clinic	Fort Worth	Texas	Recruiting
Be Well Clinical Studies - Round Rock	Round Rock	Texas	Recruiting
Flourish Research - San Antonio Medical Trials	San Antonio	Texas	Recruiting
Endeavor Clinical Trials	San Antonio	Texas	Recruiting
Consano Clinical Research, LLC	Shavano Park	Texas	Recruiting
Charlottesville Medical Research	Charlottesville	Virginia	Recruiting
Rainier Clinical Research Center	Renton	Washington	Recruiting

On this site

📄 Praluent (alirocumab) drug profile →

More Regeneron Pharmaceuticals trials in the USA

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD) Recruiting

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) Recruiting

Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy Recruiting

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Recruiting

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab Recruiting

Other trials for the same condition

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension Active, not recruiting

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07477704 on ClinicalTrials.gov ↗ ← All trials in the USA